Optimer Pharmaceuticals
A biopharmaceutical company focused on discovering, developing and commercializing.
Launch date
Employees
Market cap
AUD451.5b
Enterprise valuation
AUD492.3b (Public information from Sep 2024)
Share price
$118.64 MRK
San Diego California (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 46.8b | 48.0b | 48.7b | 59.3b | 60.1b | 64.1b | 68.5b |
| % growth | 11 % | 2 % | 1 % | 22 % | 1 % | 7 % | 7 % |
| EBITDA | 12.9b | 9.1b | 13.9b | 18.6b | 7.5b | - | - |
| % EBITDA margin | 27 % | 19 % | 28 % | 31 % | 13 % | - | - |
| Profit | 9.8b | 7.1b | 13.0b | 14.5b | 365m | - | - |
| % profit margin | 21 % | 15 % | 27 % | 24 % | 1 % | - | - |
| R&D budget | 9.9b | 13.6b | 12.2b | 13.5b | 30.5b | - | - |
| R&D % of revenue | 21 % | 28 % | 25 % | 23 % | 51 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$32.0m | Series B | ||
$12.0m | Series C | ||
$22.2m | Series D | ||
| N/A | $49.0m | IPO | |
$535m Valuation: $535m | Acquisition | ||
| Total Funding | AUD102m | ||
